Berlth Felix, Hoelscher Arnulf Heinrich
Department of Surgery, Division of Gastrointestinal Surgery, Seoul National University Hospital, Seoul, Korea.
Center of Esophageal and Gastric Surgery, Agaplesion Markus Hospital, Frankfurt, Germany.
J Gastric Cancer. 2019 Jun;19(2):139-147. doi: 10.5230/jgc.2019.19.e18. Epub 2019 May 20.
The incidence of esophagogastric junction (EGJ) cancer has been significantly increasing in Western countries. Appropriate planning for surgical therapy requires a reliable classification of EGJ cancers with respect to their exact location. Clinically, the most accepted classification of EGJ cancers is "adenocarcinoma of the EGJ" (AEG or "Siewert"), which divides tumor center localization into AEG type I (distal esophagus), AEG type II ("true junction"), and AEG type III (subcardial stomach). Treatment strategies in western countries routinely employ perioperative chemotherapy or neoadjuvant chemoradiation for cases of locally advanced cancers. The standard surgical treatment strategies are esophagectomy for AEG type I and gastrectomy for AEG type III cancers. For "true junctional cancers," i.e., AEG type II, whether the extension of resection in the oral or aboral direction represents the most effective surgical therapy remains debatable. This article reviews the history of surgical EGJ cancer treatment and current surgical strategies from a Western perspective.
在西方国家,食管胃交界(EGJ)癌的发病率一直在显著上升。为手术治疗进行适当规划需要对EGJ癌的确切位置进行可靠分类。临床上,EGJ癌最被认可的分类是“EGJ腺癌”(AEG或“Siewert”分类),它将肿瘤中心定位分为AEG I型(食管远端)、AEG II型(“真正的交界部”)和AEG III型(贲门下胃)。在西方国家,对于局部晚期癌症病例,治疗策略通常采用围手术期化疗或新辅助放化疗。标准的手术治疗策略是AEG I型行食管切除术,AEG III型癌行胃切除术。对于“真正的交界部癌”,即AEG II型,在口侧或肛侧方向扩大切除是否代表最有效的手术治疗仍存在争议。本文从西方视角回顾了EGJ癌手术治疗的历史及当前的手术策略。